VEGFA and neoplasm: In preclinical models, targeted medicines aimed against EGFR, such as cetuximab and panitumumab, and those directed against VEGF, such as bevacizumab, have been demonstrated to generate a more immunogenic tumor profile, and so could be useful adjuncts to CRC [64].